Menopausal hormone therapy and coronary heart disease: the roller-coaster history

References

• Collins JB. Menopause. Prim Care. 1988;15(3):593–606. doi: 10.1016/S0095-4543(21)01278-1.
   PubMed Web of Science ®Google Scholar
• Buckler H. The menopause transition: endocrine changes and clinical symptoms. J Br Menopause Soc. 2005;11(2):61–65. doi: 10.1258/136218005775544525.
   PubMedGoogle Scholar
• Nudy M, Jiang X, Aragaki AK, et al. The severity of vasomotor symptoms and number of menopausal symptoms in postmenopausal women and select clinical health outcomes in the women’s health initiative calcium and vitamin D randomized clinical trial. Menopause. 2020;27(11):1265–1273. doi: 10.1097/GME.0000000000001667.
   PubMed Web of Science ®Google Scholar
• Nudy M, Aragaki AK, Jiang X, et al. The severity of individual menopausal symptoms, cardiovascular disease, and all-cause mortality in the Women’s Health Initiative Observational Cohort. Menopause. 2022;29(12):1365–1374. doi: 10.1097/GME.0000000000002089.
   PubMedGoogle Scholar
• Schnatz PF, Nudy M, O’Sullivan DM, et al. Coronary artery vitamin D receptor expression and plasma concentrations of 25-hydroxyvitamin D: their association with atherosclerosis. Menopause. 2012;19(9):967–973. doi: 10.1097/gme.0b013e31824cfa8f.
   PubMed Web of Science ®Google Scholar
• Schnatz PF, Nudy M, O’Sullivan DM, et al. The quantification of vitamin D receptors in coronary arteries and their association with atherosclerosis. Maturitas. 2012;73(2):143–147. doi: 10.1016/j.maturitas.2012.03.014.
   PubMed Web of Science ®Google Scholar
• Nudy M, Xie R, O’Sullivan DM, et al. Association of coronary artery vitamin D receptor expression and select systemic risk factors for coronary artery atherosclerosis. Climacteric. 2022;25(4):369–375. doi: 10.1080/13697137.2021.1985992.
   PubMed Web of Science ®Google Scholar
• Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med. 2005;118 Suppl 12B(12):64–73. doi: 10.1016/j.amjmed.2005.09.059.
   PubMed Web of Science ®Google Scholar
• Wilson RA. Feminine forever. New York (NY): Evans; 1966. p. 224.
   Google Scholar
• Stadel BV. Estrogen therapy and endometrial carcinoma. Am J Obstet Gynecol. 1976;125(4):571–573. doi: 10.1016/0002-9378(76)90386-0.
   PubMed Web of Science ®Google Scholar
• Weiss NS, Szekely DR, Austin DF. Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976;294(23):1259–1262. doi: 10.1056/NEJM197606032942303.
   PubMed Web of Science ®Google Scholar
• Gambrell RD. Prevention of endometrial cancer with progestogens. Maturitas. 1986;8(2):159–168. doi: 10.1016/0378-5122(86)90022-8.
   PubMed Web of Science ®Google Scholar
• Panel T. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause. 2022;29(7):767–794. doi: 10.1097/GME.0000000000002028.
   PubMed Web of Science ®Google Scholar
• Jiang X, Kagan R. Hormone therapy for postmenopausal osteoporosis management. Climacteric. 2022;25(1):50–55. doi: 10.1080/13697137.2021.1957818.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Stevenson JC. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric. 2012;15(3):263–266. doi: 10.3109/13697137.2012.659975.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Sarrel PM. Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials? Climacteric. 2018;21(6):521–528. doi: 10.1080/13697137.2018.1514008.
   PubMed Web of Science ®Google Scholar
• Rocca WA, Mielke MM, Gazzuola Rocca L, et al. Premature or early bilateral oophorectomy: a 2021 update. Climacteric. 2021;24(5):466–473. doi: 10.1080/13697137.2021.1893686.
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345(oct09 2):e6409–e6409. doi: 10.1136/bmj.e6409.
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–1314. doi: 10.1001/jama.2011.382.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009;122(11):1016–1022.e1. doi: 10.1016/j.amjmed.2009.05.021.
   PubMed Web of Science ®Google Scholar
• Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;2015(3):CD002229. doi: 10.1002/14651858.CD002229.pub4.
   PubMedGoogle Scholar
• Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause. 2011;18(11):1172–1177. doi: 10.1097/gme.0b013e31821b01c7.
   PubMed Web of Science ®Google Scholar
• Armeni E, Paschou SA, Goulis DG, et al. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101561. doi: 10.1016/j.beem.2021.101561.
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Sullivan SD, Nelson LM. Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril. 2016;106(7):1580–1587. doi: 10.1016/j.fertnstert.2016.09.018.
   PubMed Web of Science ®Google Scholar
• El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):e506–e532. doi: 10.1161/CIR.0000000000000912.
   PubMed Web of Science ®Google Scholar
• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–e639. doi: 10.1161/CIR.0000000000001052.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85(4):447–452. doi: 10.7326/0003-4819-85-4-447.
   PubMed Web of Science ®Google Scholar
• Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med. 1978;89(2):157–161. doi: 10.7326/0003-4819-89-2-157.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol. 1979;44(1):53–59. doi: 10.1016/0002-9149(79)90250-9.
   PubMed Web of Science ®Google Scholar
• Arora S, Stouffer GA, Kucharska-Newton AM, et al. Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction. Circulation. 2019;139(8):1047–1056. doi: 10.1161/CIRCULATIONAHA.118.037137.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kapoor E, Moyer AM, et al. Statin therapy: does sex matter? Menopause. 2019;26(12):1425–1435. doi: 10.1097/GME.0000000000001412.
   PubMed Web of Science ®Google Scholar
• Schnatz PF. Hormonal therapy: does it increase or decrease cardiovascular risk? Obstet Gynecol Surv. 2006;61(10):673–681. doi: 10.1097/01.ogx.0000238674.98471.bb.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med. 1991;325(11):756–762. doi: 10.1056/NEJM199109123251102.
   PubMed Web of Science ®Google Scholar
• Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI trial. JAMA. 1995;273(3):199–208.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA. 1998;280(7):605–613. doi: 10.1001/jama.280.7.605.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi: 10.1001/jama.288.3.321.
   PubMed Web of Science ®Google Scholar
• Ostrzenski A, Ostrzenska KM. WHI clinical trial revisit: imprecise scientific methodology disqualifies the study’s outcomes. Am J Obstet Gynecol. 2005;193(5):1599–1604. doi: 10.1016/j.ajog.2005.07.085.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation. 2001;104(19):2256–2259. doi: 10.1161/circ.104.19.2256.
   PubMed Web of Science ®Google Scholar
• Utian WH. A decade post WHI, menopausal hormone therapy comes full circle–need for independent commission. Climacteric. 2012;15(4):320–325. doi: 10.3109/13697137.2012.678916.
   PubMed Web of Science ®Google Scholar
• Huang AJ, Sawaya GF, Vittinghoff E, et al. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause. 2018;25(11):1286–1290. doi: 10.1097/GME.0000000000001230.
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49–57. doi: 10.1001/jama.288.1.49.
   PubMed Web of Science ®Google Scholar
• Son JW, Koh KK, Ahn JY, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol. 2003;88(1):77–82. doi: 10.1016/s0167-5273(02)00368-6.
   PubMed Web of Science ®Google Scholar
• Hwang J, Hodis HN, Hsiai TK, et al. Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis. 2006;189(1):76–82. doi: 10.1016/j.atherosclerosis.2005.11.026.
   PubMed Web of Science ®Google Scholar
• Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation. 2002;105(25):2962–2967. doi: 10.1161/01.cir.0000019406.74017.b2.
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343(8):522–529. doi: 10.1056/NEJM200008243430801.
   PubMed Web of Science ®Google Scholar
• Hwang J, Mack WJ, Xiang M, et al. Long-term effect of estrogen replacement on plasma nitric oxide levels: results from the estrogen in the prevention of atherosclerosis trial (EPAT). Atherosclerosis. 2005;181(2):375–380. doi: 10.1016/j.atherosclerosis.2004.12.046.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135(11):939–953. doi: 10.7326/0003-4819-135-11-200112040-00005.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349(6):535–545. doi: 10.1056/NEJMoa030830.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1729–1738. doi: 10.1001/jama.290.13.1729.
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–534. doi: 10.1056/NEJMoa030808.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–3253. Jun 25 doi: 10.1001/jama.289.24.3243.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712. doi: 10.1001/jama.291.14.1701.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477. doi: 10.1001/jama.297.13.1465.
   PubMed Web of Science ®Google Scholar
• Langer RD. The evidence base for HRT: what can we believe? Climacteric. 2017;20(2):91–96. doi: 10.1080/13697137.2017.1280251.
   PubMed Web of Science ®Google Scholar
• Brown S. Shock, terror and controversy: how the media reacted to the Women’s Health Initiative. Climacteric. 2012;15(3):275–280. doi: 10.3109/13697137.2012.660048.
   PubMed Web of Science ®Google Scholar
• Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA. 2004;292(16):1983–1988. doi: 10.1001/jama.292.16.1983.
   PubMed Web of Science ®Google Scholar
• Barbaglia G, Macià F, Comas M, et al. Trends in hormone therapy use before and after publication of the Women’s Health Initiative trial: 10 years of follow-up. Menopause. 2009;16(5):1061–1064. doi: 10.1097/gme.0b013e3181a02b44.
   PubMed Web of Science ®Google Scholar
• Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143(10):971–978. doi: 10.1093/oxfordjournals.aje.a008678.
   PubMed Web of Science ®Google Scholar
• Hodis H, Mack W. Randomized controlled trials and the effects of postmenopausal hormone therapy on cardiovascular disease: facts, hypotheses and clinical perspective. In: Lobo R, editor. Treatment of the postmenopausal woman. Cambridge (MA): Elsevier Academic Press; 2007. p. 529–564.
   Google Scholar
• Hodis HN, Mack WJ, Shoupe D, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause. 2015;22(4):391–401. doi: 10.1097/GME.0000000000000343.
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Manson JE. The timing hypothesis: do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism. 2016;65(5):794–803. doi: 10.1016/j.metabol.2016.01.004.
   PubMed Web of Science ®Google Scholar
• Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17(1):217–221. doi: 10.1161/01.atv.17.1.217.
   PubMed Web of Science ®Google Scholar
• Williams JK, Suparto I. Hormone replacement therapy and cardiovascular disease: lessons from a monkey model of postmenopausal women. ILAR J. 2004;45(2):139–146. doi: 10.1093/ilar.45.2.139.
   PubMed Web of Science ®Google Scholar
• Williams JK, Anthony MS, Honoré EK, et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995;15(7):827–836. doi: 10.1161/01.atv.15.7.827.
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Appt SE. Controversies about HRT–lessons from monkey models. Maturitas. 2005;51(1):64–74. doi: 10.1016/j.maturitas.2005.02.016.
   PubMed Web of Science ®Google Scholar
• Wagner JD, Clarkson TB, St Clair RW, et al. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest. 1991;88(6):1995–2002. doi: 10.1172/JCI115526.
   PubMed Web of Science ®Google Scholar
• Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis. 1990;10(6):1051–1057. doi: 10.1161/01.atv.10.6.1051.
   PubMedGoogle Scholar
• Manson JE, Aragaki AK, Bassuk SS, et al. Menopausal estrogen-alone therapy and health outcomes in women with and without bilateral oophorectomy: a randomized trial. Ann Intern Med. 2019;171(6):406–414. doi: 10.7326/M19-0274.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231. doi: 10.1056/NEJMoa1505241.
   PubMed Web of Science ®Google Scholar
• Hsia J, Criqui MH, Herrington DM, et al. Conjugated equine estrogens and peripheral arterial disease risk: the Women’s Health Initiative. Am Heart J. 2006;152(1):170–176. doi: 10.1016/j.ahj.2005.09.005.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318(10):927–938. doi: 10.1001/jama.2017.11217.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–260. doi: 10.7326/M14-0353.
   PubMed Web of Science ®Google Scholar
• Ostberg JE, Storry C, Donald AE, et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf). 2007;66(4):557–564. doi: 10.1111/j.1365-2265.2007.02772.x.
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591–2602. doi: 10.1056/NEJMoa071513.
   PubMed Web of Science ®Google Scholar
• Nudy M, Chinchilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. Int J Cardiol Heart Vasc. 2019;22:123–131. doi: 10.1016/j.ijcha.2019.01.001.
   PubMed Web of Science ®Google Scholar
• Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG. 2002;109(9):1056–1062. doi: 10.1111/j.1471-0528.2002.01544.x.
   PubMed Web of Science ®Google Scholar
• Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(11):4012–4020. doi: 10.1210/jc.2015-2237.
   PubMed Web of Science ®Google Scholar
• Shufelt CL, Merz CN, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study. Menopause. 2014;21(3):260–266. doi: 10.1097/GME.0b013e31829a64f9.
   PubMed Web of Science ®Google Scholar
• Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001;85(04):619–625. doi: 10.1055/s-0037-1615643.
   PubMedGoogle Scholar
• (NAMS) TNAMS. NAMS 3rd Utian Translational Science Symposium, October 2016, Orlando, Florida a conversation about hormone therapy: is there an appropriate dose, route, and duration of use? Menopause. 2017;24(11):1221–1235. doi: 10.1097/GME.0000000000000986.
   PubMed Web of Science ®Google Scholar